CTOs on the Move

Scribe Therapeutics

www.scribetx.com

 
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.scribetx.com
  • 1150 Marina Village Pkwy
    Alameda, CA USA 94501
  • Phone: 908.642.7374

Executives

Name Title Contact Details

Similar Companies

Nano-C

Nano-C is a Westwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Life Molecular Imaging

Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit https://life-mi.com. https://neuraceq.com/wp-content/uploads/USPI-DOC-1118-v5.1-May-2023.pdf

BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.

Volastra Therapeutics

Volastra aims to extend the lives of patients with cancer by leveraging unique insights into chromosomal instability. Moving away from primary tumor models to target the site of metastasis in the toughest-to-treat solid tumors, we are altering the treatment paradigm for metastatic cancers.

RootPath Genomics

RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.